
    
      Protocol No: TLC178A1001

      Name of Finished Product: LipoVNB (Liposomal Vinorelbine Tartrate)

      Title of Study:

      Phase I/IIa, Open label, Dose-escalation Study Investigating the Safety, Tolerability, and
      Pharmacokinetics of Intravenous Liposomal Vinorelbine Tartrate Injection in Patients with
      Advanced Malignancy.

      Study duration:

      Every patient will have a treatment period of 4-week cycles until completion of 6 cycles,
      progression of disease or intolerance, withdrawal of consent or Investigator's judgment,
      whichever occurs first.
    
  